QureBio has recently garnered tens of millions of yuan in its Pre-B financing round from Xinheng Lida Capital and other relevant institutions.
Proceeds from this financing round will be used primarily to advance the preclinical development of the Q-1802 and Q-1801 projects.
Prior to this round, QureBio had closed three rounds of financing including the multimillion-yuan Series A+ round by Shenzhen Capital Group, multimillion-yuan Series A round by Jundu Investment and Wosheng Investment in August 2019, and the angel round worth nearly 10 million yuan in May 2017.
Founded in July 2017, QureBio, based in Zhangjiang, Shanghai, is a developer of innovative macromolecular biopharmaceutical drug. The company aims to develop new therapeutic drugs for refractory cancers, autoimmune diseases and metabolic disorders.
The company has several independent innovation platforms for antibody drug development, including a hybridoma antibody humanization platform, a phage demonstration technology platform, a single-domain antibody platform and an antibody engineering platform.
QureBio relies on its own platform to develop new and proprietary biologics. Currently, the company has nearly ten pipeline projects in development, mostly targeting solid tumors.